Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver

Next Previous
Trial Profile

A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Melphalan (Primary) ; Antineoplastics
  • Indications Liver metastases
  • Focus Registrational; Therapeutic Use
  • Sponsors Delcath Systems

Most Recent Events

  • 06 Apr 2026 According to Delcath systems media release, company announced that its proprietary CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026).
  • 29 Mar 2018 According to a Delcath systems media release, results from this were presented at the 2018 Society of Surgical Oncology Annual Cancer Symposium (SSO)
  • 09 Dec 2015 According to a Delcath media release, results from this trial were published in Annals of Surgical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top